SER Serina Therapeutics, Inc.

MIXED Impact: 5/10 Insider Cluster (2 insiders)
Horizon weeks Filed May 26, 2026 Processed 17d 16h ago
Insider cluster: 2 insiders, $38K total
Latest settled — T+5d ⚠ clustered
SER ▼ -0.56% at T+5d
NEUTRAL call ✗ call lost -0.56% · α vs SPY -1.02% · entry $1.80 → $1.79
Next anchor: T+20d in 11d
Currently $1.84 · +2.22% from $1.80 entry
Entry anchored
May 26, 2026
via day open
T+1d
+8.33%
call +8.33% · α +7.78%
$1.95
settled 17d ago
T+5d
-0.56%
call -0.56% · α -1.02%
$1.79
settled 11d ago
T+20d
call — · α —
in 11d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, representing ~0.13% of the $30M market cap. This follows the company's Q1 2026 earnings release (net loss widened to -$6.9M) and a recently filed S-3 registration for up to 16.45M shares (potential >100% dilution). The insider buys are modest in size and occur amid a capital raise registration that enables selling shareholders to exit, making the signal ambiguous.

Key Financial Metrics

Direction
buying
Total Value
$38.0K
Insiders
2

Actionable Insight

The insider buys are small and may reflect confidence in SER-252 clinical progress, but the S-3 resale registration filed 4 days later creates massive overhang. Watch for any Form 4 filings by Dr. Bailey or other PIPE participants selling into the registration — that would confirm the bearish dilution thesis. The next catalyst is TFL data from the SAD arm in H1 2027, providing a long wait with significant dilution risk in the interim.

Key Facts

  • Two directors purchased $38K in open-market transactions over 3 days (May 19–21, 2026).
  • Purchases represent ~0.13% of the $30M market cap — below the 0.5% materiality threshold.
  • S-3 filed May 22 registers up to 16.45M shares for resale by PIPE investors, including insider Dr. Gregory H. Bailey.
  • Q1 2026 net loss widened to -$6.9M from -$4.8M YoY; cash position $24.5M as of March 31, 2026.
  • Phase 1b registrational study of SER-252 underway; TFL data from SAD arm targeted for H1 2027.

Financial Impact

Insider purchases of $38K are trivial relative to $30M market cap; S-3 registration enables up to ~110% dilution at current share count.

dilutioncash runway

Risk Factors

  • S-3 registration enables >100% dilution from PIPE shares and warrants; selling pressure likely.
  • Going concern doubt flagged in Q1 2026 10-Q; net loss widening with no near-term revenue.
  • Insider purchases are small relative to market cap and may be symbolic rather than conviction-driven.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SER-1779838439269
6 reports for SER
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +5.73%May 22, 2026
Filters
Rows
Reports for SER — sortable, filterable
Type Now
Jun 4, 2026
9d ago
EFFECT
BEARISH ★ 7/10
$1.86 $1.88▼ −1.08%▼ −3.67%$1.84 (+1.08%)
May 26, 2026
17d ago
Insider Cluster
MIXED ★ 5/10
$1.80 $1.95▲ +8.33%▲ +7.78%$1.84 (+2.22%)
May 26, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$1.80 $1.95▼ −8.33%▼ −7.78%$1.84 (−2.22%)
May 22, 2026
21d ago
S-3
BEARISH ★ 7/10
$1.92 $1.86▲ +3.13%▲ +3.08%$1.84 (+4.17%)
Mar 27, 2026
11w ago
10-K/A
NEUTRAL ★ 2/10
$2.27 $1.80▼ −20.70%▼ −20.35%$1.84 (−18.94%)
Mar 25, 2026
11w ago
Press Release
MIXED ★ 7/10
$2.61 $2.27▼ −13.03%▼ −11.35%$1.84 (−29.50%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (45h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access